Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
DCPH Price/Volume Stats
| Current price | $14.67 | 52-week high | $17.73 |
| Prev. close | $14.23 | 52-week low | $9.90 |
| Day low | $14.05 | Volume | 394,200 |
| Day high | $14.69 | Avg. volume | 524,755 |
| 50-day MA | $15.65 | Dividend yield | N/A |
| 200-day MA | $14.05 | Market Cap | 1.19B |
DCPH Stock Price Chart Interactive Chart >
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Latest DCPH News From Around the Web
Below are the latest news stories about DECIPHERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DCPH as an investment opportunity.
Deciphera Pharmaceuticals CEO Steven Hoerter Sells Over 30,000 SharesSteven Hoerter, the President and CEO of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH), has recently sold a significant number of shares in the company. |
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 97% Above Its Share PriceKey Insights The projected fair value for Deciphera Pharmaceuticals is US$29.64 based on 2 Stage Free Cash Flow to... |
Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue?Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Insider Sell Alert: Daniel Martin of Deciphera Pharmaceuticals Inc Cashes Out SharesIn the realm of biopharmaceuticals, insider trading activity often garners significant attention from investors seeking to understand the internal perspectives of a company's executives. |
Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
DCPH Price Returns
| 1-mo | -5.35% |
| 3-mo | 8.03% |
| 6-mo | 43.68% |
| 1-year | -0.34% |
| 3-year | 27.57% |
| 5-year | 142.48% |
| YTD | -9.05% |
| 2023 | -1.59% |
| 2022 | 67.76% |
| 2021 | -31.52% |
| 2020 | -8.31% |
| 2019 | 196.52% |
Continue Researching DCPH
Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...